These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 39229055)

  • 1. Discovery of potent SARS-CoV-2 nsp3 macrodomain inhibitors uncovers lack of translation to cellular antiviral response.
    Lee AA; Amick I; Aschenbrenner JC; Barr HM; Benjamin J; Brandis A; Cohen G; Diaz-Tapia R; Duberstein S; Dixon J; Cousins D; Fairhead M; Fearon D; Frick J; Gayvert J; Godoy AS; Griffin EJ; Huber K; Koekemoer L; Lahav N; Marples PG; McGovern BL; Mehlman T; Robinson MC; Singh U; Szommer T; Tomlinson CWE; Vargo T; von Delft F; Wang S; White K; Williams E; Winokan M
    bioRxiv; 2024 Aug; ():. PubMed ID: 39229055
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Targeting SARS-CoV-2 Nsp3 macrodomain structure with insights from human poly(ADP-ribose) glycohydrolase (PARG) structures with inhibitors.
    Brosey CA; Houl JH; Katsonis P; Balapiti-Modarage LPF; Bommagani S; Arvai A; Moiani D; Bacolla A; Link T; Warden LS; Lichtarge O; Jones DE; Ahmed Z; Tainer JA
    Prog Biophys Mol Biol; 2021 Aug; 163():171-186. PubMed ID: 33636189
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The SARS-CoV-2 Conserved Macrodomain Is a Mono-ADP-Ribosylhydrolase.
    Alhammad YMO; Kashipathy MM; Roy A; Gagné JP; McDonald P; Gao P; Nonfoux L; Battaile KP; Johnson DK; Holmstrom ED; Poirier GG; Lovell S; Fehr AR
    J Virol; 2021 Jan; 95(3):. PubMed ID: 33158944
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Discovery of compounds that inhibit SARS-CoV-2 Mac1-ADP-ribose binding by high-throughput screening.
    Roy A; Alhammad YM; McDonald P; Johnson DK; Zhuo J; Wazir S; Ferraris D; Lehtiö L; Leung AKL; Fehr AR
    Antiviral Res; 2022 Jul; 203():105344. PubMed ID: 35598780
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Macrodomain Mac1 of SARS-CoV-2 Nonstructural Protein 3 Hydrolyzes Diverse ADP-ribosylated Substrates.
    Chea C; Lee DY; Kato J; Ishiwata-Endo H; Moss J
    bioRxiv; 2023 Feb; ():. PubMed ID: 36945431
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The SARS-CoV-2 conserved macrodomain is a mono-ADP-ribosylhydrolase.
    Alhammad YMO; Kashipathy MM; Roy A; Gagné JP; McDonald P; Gao P; Nonfoux L; Battaile KP; Johnson DK; Holmstrom ED; Poirier GG; Lovell S; Fehr AR
    bioRxiv; 2020 Oct; ():. PubMed ID: 32511412
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Design, synthesis and evaluation of inhibitors of the SARS-CoV-2 nsp3 macrodomain.
    Sherrill LM; Joya EE; Walker A; Roy A; Alhammad YM; Atobatele M; Wazir S; Abbas G; Keane P; Zhuo J; Leung AKL; Johnson DK; Lehtiö L; Fehr AR; Ferraris D
    Bioorg Med Chem; 2022 Aug; 67():116788. PubMed ID: 35597097
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The SARS-CoV-2 Nsp3 macrodomain reverses PARP9/DTX3L-dependent ADP-ribosylation induced by interferon signaling.
    Russo LC; Tomasin R; Matos IA; Manucci AC; Sowa ST; Dale K; Caldecott KW; Lehtiö L; Schechtman D; Meotti FC; Bruni-Cardoso A; Hoch NC
    J Biol Chem; 2021 Sep; 297(3):101041. PubMed ID: 34358560
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Discovery of compounds that inhibit SARS-CoV-2 Mac1-ADP-ribose binding by high-throughput screening.
    Roy A; Alhammad YM; McDonald P; Johnson DK; Zhuo J; Wazir S; Ferraris D; Lehtiö L; Leung AKL; Fehr AR
    bioRxiv; 2022 Mar; ():. PubMed ID: 35262075
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The Mac1 ADP-ribosylhydrolase is a Therapeutic Target for SARS-CoV-2.
    Suryawanshi RK; Jaishankar P; Correy GJ; Rachman MM; O'Leary PC; Taha TY; Zapatero-Belinchón FJ; McCavittMalvido M; Doruk YU; Stevens MGV; Diolaiti ME; Jogalekar MP; Richards AL; Montano M; Rosecrans J; Matthay M; Togo T; Gonciarz RL; Gopalkrishnan S; Neitz RJ; Krogan NJ; Swaney DL; Shoichet BK; Ott M; Renslo AR; Ashworth A; Fraser JS
    bioRxiv; 2024 Aug; ():. PubMed ID: 39149230
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Unique Mutations in the Murine Hepatitis Virus Macrodomain Differentially Attenuate Virus Replication, Indicating Multiple Roles for the Macrodomain in Coronavirus Replication.
    Voth LS; O'Connor JJ; Kerr CM; Doerger E; Schwarting N; Sperstad P; Johnson DK; Fehr AR
    J Virol; 2021 Jul; 95(15):e0076621. PubMed ID: 34011547
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A single inactivating amino acid change in the SARS-CoV-2 NSP3 Mac1 domain attenuates viral replication in vivo.
    Taha TY; Suryawanshi RK; Chen IP; Correy GJ; McCavitt-Malvido M; O'Leary PC; Jogalekar MP; Diolaiti ME; Kimmerly GR; Tsou CL; Gascon R; Montano M; Martinez-Sobrido L; Krogan NJ; Ashworth A; Fraser JS; Ott M
    PLoS Pathog; 2023 Aug; 19(8):e1011614. PubMed ID: 37651466
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Structure-Based High-Throughput Virtual Screening and Molecular Dynamics Simulation for the Discovery of Novel SARS-CoV-2 NSP3 Mac1 Domain Inhibitors.
    Yazdani B; Sirous H; Brogi S; Calderone V
    Viruses; 2023 Nov; 15(12):. PubMed ID: 38140532
    [TBL] [Abstract][Full Text] [Related]  

  • 14. An Update on the Current State of SARS-CoV-2 Mac1 Inhibitors.
    O'Connor JJ; Ferraris D; Fehr AR
    Pathogens; 2023 Oct; 12(10):. PubMed ID: 37887737
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Discovery and Development Strategies for SARS-CoV-2 NSP3 Macrodomain Inhibitors.
    Schuller M; Zarganes-Tzitzikas T; Bennett J; De Cesco S; Fearon D; von Delft F; Fedorov O; Brennan PE; Ahel I
    Pathogens; 2023 Feb; 12(2):. PubMed ID: 36839595
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A single inactivating amino acid change in the SARS-CoV-2 NSP3 Mac1 domain attenuates viral replication and pathogenesis
    Taha TY; Suryawanshi RK; Chen IP; Correy GJ; O'Leary PC; Jogalekar MP; McCavitt-Malvido M; Diolaiti ME; Kimmerly GR; Tsou CL; Martinez-Sobrido L; Krogan NJ; Ashworth A; Fraser JS; Ott M
    bioRxiv; 2023 May; ():. PubMed ID: 37131711
    [TBL] [Abstract][Full Text] [Related]  

  • 17. An MHV macrodomain mutant predicted to lack ADP-ribose binding activity is severely attenuated, indicating multiple roles for the macrodomain in coronavirus replication.
    Voth LS; O'Connor JJ; Kerr CM; Doerger E; Schwarting N; Sperstad P; Johnson DK; Fehr AR
    bioRxiv; 2021 Mar; ():. PubMed ID: 33821264
    [TBL] [Abstract][Full Text] [Related]  

  • 18. SARS-CoV-2 Mac1 is required for IFN antagonism and efficient virus replication in mice.
    Alhammad YM; Parthasarathy S; Ghimire R; O'Connor JJ; Kerr CM; Pfannenstiel JJ; Chanda D; Miller CA; Unckless RL; Zuniga S; Enjuanes L; More S; Channappanavar R; Fehr AR
    bioRxiv; 2023 Apr; ():. PubMed ID: 37066301
    [TBL] [Abstract][Full Text] [Related]  

  • 19. High-Throughput Screening and Quantum Mechanics for Identifying Potent Inhibitors Against Mac1 Domain of SARS-CoV-2 Nsp3.
    Selvaraj C; Dinesh DC; Panwar U; Boura E; Singh SK
    IEEE/ACM Trans Comput Biol Bioinform; 2021; 18(4):1262-1270. PubMed ID: 33306471
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Fragment Binding to the Nsp3 Macrodomain of SARS-CoV-2 Identified Through Crystallographic Screening and Computational Docking.
    Schuller M; Correy GJ; Gahbauer S; Fearon D; Wu T; Díaz RE; Young ID; Martins LC; Smith DH; Schulze-Gahmen U; Owens TW; Deshpande I; Merz GE; Thwin AC; Biel JT; Peters JK; Moritz M; Herrera N; Kratochvil HT; ; Aimon A; Bennett JM; Neto JB; Cohen AE; Dias A; Douangamath A; Dunnett L; Fedorov O; Ferla MP; Fuchs M; Gorrie-Stone TJ; Holton JM; Johnson MG; Krojer T; Meigs G; Powell AJ; ; Rangel VL; Russi S; Skyner RE; Smith CA; Soares AS; Wierman JL; Zhu K; Jura N; Ashworth A; Irwin J; Thompson MC; Gestwicki JE; von Delft F; Shoichet BK; Fraser JS; Ahel I
    bioRxiv; 2020 Nov; ():. PubMed ID: 33269349
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.